Abbott Laboratories
Bear Case (25th pct.)
-52.3% vs price
Base Case (Median)
-45.6% vs price
Bull Case (75th pct.)
-35.3% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $12.57 | -88.0% | High (40%) |
| PE Comparable | $69.24 | -33.8% | Medium (25%) |
| Growth Trajectory DCF | $56.90 | -45.6% | Medium (20%) |
| Graham Number | $45.70 | -56.3% | Medium (40%) |
| EV/EBITDA | $66.13 | -36.8% | Medium (20%) |
| EV/FCF | $84.46 | -19.2% | Medium (20%) |
| Earnings Power Value | $54.05 | -48.3% | Medium (50%) |
Based on 7 out of 8 methods, ABT appears overvalued at the current price of $104.58. The base case fair value of $56.90 implies 45.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.